Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences

By afschroeder • June 19, 2026

Bruyat D, Girard N, Heudel P, Penel N, Le Deley MC, Diallo I, Boher JM, Zemmour C, Chanez B, Madroszyk A, Gravis G, Billon E, Lisberg A, Collineau B, Beaufils M, Gonçalves A, Tejeda M, Chrétien AS, Rochigneux P. Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences. Cancer Commun (Lond). 2026 Jun 17;46:0035. doi: 10.34133/cancomm.0035. PMID: 42318065; PMCID: PMC13273061.

Tags: Hematology/Oncology, Publications

Related Posts

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

Peters S, Meyer ML, André F, Argilés G, Azizi AA, Banerjee S, Burgers S, Curigliano G, Drago JZ, Fontana E, Garon EB, Klümper N, Le[...]

Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study

Modi S, Murthy RK, Chien AJ, Lin NU, McAndrew NP, Specht JM, Zelnak AB, Ramos J, Xie D, Ho J, Inoue JK, Carey LA, Hamilton[...]

Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van[...]